BIONET Corp.

Total Valuation

BIONET Corp. carries a market capitalization of 3.53B, placing it among publicly traded companies globally. Its enterprise value stands at 4.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BIONET Corp. currently has 50.31M shares outstanding.

Valuation Ratios

BIONET Corp. trades at a trailing price-to-earnings ratio of 101.84. The price-to-sales ratio is 4.24, and the price-to-book ratio stands at 8.98.

Enterprise Valuation

On an enterprise value basis, BIONET Corp. trades at an EV/EBITDA multiple of 1,052.06 and an EV/FCF ratio of 17.62. The EV/Sales ratio of 3.99 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1,052.06 provides insight into valuation relative to core operating earnings.

Financial Position

BIONET Corp. maintains a current ratio of 4.62, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.15, indicating elevated leverage, while an interest coverage ratio of -8.06 demonstrates limited ability to service its debt obligations.

Financial Efficiency

BIONET Corp. posts a return on equity of 8.58 and a return on invested capital of -0.02.

Taxes

Over the trailing twelve months, BIONET Corp. has paid 18.43M in income taxes, reflecting an effective tax rate of 95.60.

Stock Price Statistics

BIONET Corp.'s stock has declined approximately -3.86266% over the past 52 weeks. The 50-day moving average sits at 74.97, while the 200-day moving average is 88.69.

Income Statement

Over the trailing twelve months, BIONET Corp. generated 1.24B in revenue and converted that into 51.43M in net income, yielding earnings per share of 0.02. EBITDA reached -12.10M, while operating income came in at -12.10M.

Balance Sheet

BIONET Corp. holds 1.40B in cash and equivalents against 116.27M in total debt, resulting in a net debt position of -183.58M. Total book value stands at 583.07M, with working capital of 1.47B providing operational flexibility.

Cash Flow

BIONET Corp. produced 148.04M in operating cash flow over the past twelve months. After subtracting -132.18M in capital expenditures, free cash flow totaled 15.86M - equivalent to 0.31 per share.

Margins

BIONET Corp. operates with a gross margin of 55.30, reflecting its pricing power and cost economics. The operating margin of -0.98 and net profit margin of 4.16 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

BIONET Corp.'s most recent stock split took place on September 19, 2024 with a 100:107 split ratio.

Scores

BIONET Corp. posts an Altman Z-Score of 4.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.